The FTSE 100 advanced 0.3% to close at 9,720.51, with heavyweight resource names providing much of the upward momentum. The mid-cap FTSE 250 also added just over 0.3% to 22,165.17,
Reeves to unveil stamp duty holiday to revive London IPO market
Rachel Reeves will announce a three-year stamp duty holiday for newly listed companies in her Budget, in a bid to reignite London’s struggling stock market and lure more firms to
UK Bond Auction Thrown Into Disarray as Bloomberg Terminals Crash
City of London Traders Lament ‘Fate Worse Than Death’ as Screens Go Dark
Trader’s Café With Zak Mir: The Week In Small Caps, Saturday 19th April 2025
The Death Cross There are of course many financial news and information services. Too many. There are the boring, yet snooty macro ones, like Bloomberg or CNBC, that obsess about
Elon Musk is contemplating pulling Twitter out of the EU.
Elon Musk has reportedly indicated that X, previously known as Twitter, might become unavailable in Europe to bypass new EU regulations.
Twitter alleges that Meta pilfered concepts for its competing app, Threads.
Twitter Inc (NYSE: TWTR) has warned that it might instigate legal proceedings against its competitor, Meta Platforms Inc (NASDAQ: FB), due to the striking similarities between their new app, Threads,
OKYO Pharma is scheduled to present data on their dry eye drug at an important conference.
OKYO Pharma Ltd (LSE: OKYO, NASDAQ: OKYO), a biopharmaceutical company focused on ophthalmology, is set to present two papers on their treatment for dry eye disease (DED), OK-101, at the
OKYO Pharma is all set to commence a clinical trial for dry eye treatment in the US
Activation of First Clinical Trial Site in the U.S
How Traders Can Use Twitter Effectively
While it may have initially been modelled as a microblogging platform, Twitter has, over time, become a place for traders to look out for trends in the stock market and
OKYO Pharma LTD has commenced the trial process for its treatment of dry eye disease.
OKYO Pharma Ltd (LSE: OKYO, NASDAQ: OKYO) announced that the ClinicalTrials.gov public website (ClinicalTrials.gov Identifier: NCT05759208) now includes information about its trial that assesses the safety and effectiveness of OK-101
OKYO Pharma Limited (AIM:OKYO) Custom Clearance of GMP Packaged OK-101 Drug
OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease
OKYO Pharma Limited (AIM:OKYO) Appointment to Scientific Advisory Board
OKYO Pharma Announces Appointment of Dr. Jay S. Pepose to its Scientific Advisory Board